Cargando…
Japan’s Special Approval for Emergency System During the COVID‐19 Pandemic
The development of drugs for coronavirus disease 2019 (COVID‐19) is a global challenge. In Japan, remdesivir was approved in May 2020 for COVID‐19 caused by the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection. In February 2021, a vaccine against COVID‐19 was approved. These tw...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8239700/ https://www.ncbi.nlm.nih.gov/pubmed/34032279 http://dx.doi.org/10.1002/cpt.2310 |
_version_ | 1783715101418717184 |
---|---|
author | Maeda, Hideki |
author_facet | Maeda, Hideki |
author_sort | Maeda, Hideki |
collection | PubMed |
description | The development of drugs for coronavirus disease 2019 (COVID‐19) is a global challenge. In Japan, remdesivir was approved in May 2020 for COVID‐19 caused by the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection. In February 2021, a vaccine against COVID‐19 was approved. These two approvals were made using the Special Approval for Emergency system in Japan. This Japanese system was started in 2010 and has been used to approve four drugs to date, including remdesivir and the Pfizer COVID‐19 vaccine. This paper discusses future challenges for Japan's Special Approval for Emergency system and organizes what can be learned from experiences to date. As a result, I would like to point Out the following issues. (i) Special Approval for Emergency is a system for approving drugs approved overseas, not a system for approving drugs originally developed in Japan. A system to approve drugs that have not been approved in foreign countries needs to be considered. (ii) In the Special Approval for Emergency system, it is necessary to ensure that postmarketing activities are conducted in accordance with the Risk Management Plan and the conditions of approval, to disclose the results in a timely and speedy manner, and to judge the appropriateness of continued approval based on the results of postmarketing activities. |
format | Online Article Text |
id | pubmed-8239700 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-82397002021-06-29 Japan’s Special Approval for Emergency System During the COVID‐19 Pandemic Maeda, Hideki Clin Pharmacol Ther Reviews The development of drugs for coronavirus disease 2019 (COVID‐19) is a global challenge. In Japan, remdesivir was approved in May 2020 for COVID‐19 caused by the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection. In February 2021, a vaccine against COVID‐19 was approved. These two approvals were made using the Special Approval for Emergency system in Japan. This Japanese system was started in 2010 and has been used to approve four drugs to date, including remdesivir and the Pfizer COVID‐19 vaccine. This paper discusses future challenges for Japan's Special Approval for Emergency system and organizes what can be learned from experiences to date. As a result, I would like to point Out the following issues. (i) Special Approval for Emergency is a system for approving drugs approved overseas, not a system for approving drugs originally developed in Japan. A system to approve drugs that have not been approved in foreign countries needs to be considered. (ii) In the Special Approval for Emergency system, it is necessary to ensure that postmarketing activities are conducted in accordance with the Risk Management Plan and the conditions of approval, to disclose the results in a timely and speedy manner, and to judge the appropriateness of continued approval based on the results of postmarketing activities. John Wiley and Sons Inc. 2021-06-18 2022-03 /pmc/articles/PMC8239700/ /pubmed/34032279 http://dx.doi.org/10.1002/cpt.2310 Text en © 2021 The Authors. Clinical Pharmacology & Therapeutics published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Reviews Maeda, Hideki Japan’s Special Approval for Emergency System During the COVID‐19 Pandemic |
title | Japan’s Special Approval for Emergency System During the COVID‐19 Pandemic |
title_full | Japan’s Special Approval for Emergency System During the COVID‐19 Pandemic |
title_fullStr | Japan’s Special Approval for Emergency System During the COVID‐19 Pandemic |
title_full_unstemmed | Japan’s Special Approval for Emergency System During the COVID‐19 Pandemic |
title_short | Japan’s Special Approval for Emergency System During the COVID‐19 Pandemic |
title_sort | japan’s special approval for emergency system during the covid‐19 pandemic |
topic | Reviews |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8239700/ https://www.ncbi.nlm.nih.gov/pubmed/34032279 http://dx.doi.org/10.1002/cpt.2310 |
work_keys_str_mv | AT maedahideki japansspecialapprovalforemergencysystemduringthecovid19pandemic |